ECSP077998A - Moduladores de cinasa de aminoquinolina y aminoquinazolina - Google Patents

Moduladores de cinasa de aminoquinolina y aminoquinazolina

Info

Publication number
ECSP077998A
ECSP077998A EC2007007998A ECSP077998A ECSP077998A EC SP077998 A ECSP077998 A EC SP077998A EC 2007007998 A EC2007007998 A EC 2007007998A EC SP077998 A ECSP077998 A EC SP077998A EC SP077998 A ECSP077998 A EC SP077998A
Authority
EC
Ecuador
Prior art keywords
compounds
aminoquinoline
aminoquinazoline
trkb
flt3
Prior art date
Application number
EC2007007998A
Other languages
English (en)
Inventor
Michael David Gaul
Guozhang Xu
Christian Andrew Baumann
Kevin Douglas Kreutter
Nand Baindur
Alexander J Kim
Bao-Ping Zhao
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP077998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP077998A publication Critical patent/ECSP077998A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención está dirigida a compuestos de aminoquinolina y aminoquinazolina de la fórmula I:en donde R1, R2, R3, B, Z, Q, p, q y X son como se define aquí, el uso de dichos compuestos como moduladores de proteína tirosina cinasa, particularmente inhibidores de FLT3 y/o TrkB, el uso de dichos compuestos para reducir o inhibir la actividad de cinasa de FLT3 y/o TrkB en una célula o un sujeto, y el uso de dichos compuestos para prevenir o tratar en un sujeto un trastorno proliferativo de células y/o trastornos relacionados con FLT3 y/o TrkB; la presente invención además está dirigida a composiciones farmacéuticas que comprenden los compuestos de la presente invención y a métodos para tratar condiciones tales como cánceres y otros trastornos proliferativos de células.
EC2007007998A 2005-06-10 2007-12-10 Moduladores de cinasa de aminoquinolina y aminoquinazolina ECSP077998A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938205P 2005-06-10 2005-06-10
US74732106P 2006-05-16 2006-05-16

Publications (1)

Publication Number Publication Date
ECSP077998A true ECSP077998A (es) 2008-01-23

Family

ID=37101582

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007998A ECSP077998A (es) 2005-06-10 2007-12-10 Moduladores de cinasa de aminoquinolina y aminoquinazolina

Country Status (17)

Country Link
US (1) US20070004763A1 (es)
EP (1) EP1899319A2 (es)
JP (1) JP2008543762A (es)
KR (1) KR20080028913A (es)
AR (1) AR057062A1 (es)
AU (1) AU2006258059A1 (es)
BR (1) BRPI0611621A2 (es)
CA (1) CA2611378A1 (es)
CR (1) CR9647A (es)
EA (1) EA200800014A1 (es)
EC (1) ECSP077998A (es)
GT (1) GT200600254A (es)
IL (1) IL187685A0 (es)
NO (1) NO20080168L (es)
PE (1) PE20070113A1 (es)
TW (1) TW200716598A (es)
WO (1) WO2006135649A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR102537A1 (es) * 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
CN114984016A (zh) * 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3394061B1 (en) 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
EP3452451A4 (en) * 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
US10414775B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
EA202090595A1 (ru) 2017-09-08 2020-06-29 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити Ингибиторы enpp1 и способы модуляции иммунного ответа
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
SG11202013175SA (en) 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
WO2020017569A1 (ja) 2018-07-17 2020-01-23 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
US20220226299A1 (en) * 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
CN114401955A (zh) * 2019-07-17 2022-04-26 金耐特生物制药公司 细胞周期蛋白依赖性激酶的抑制剂
CN118955502A (zh) * 2020-07-23 2024-11-15 上海赛岚生物科技有限公司 一类具有激酶抑制活性的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT344178B (de) * 1974-07-25 1978-07-10 Pfizer Verfahren zur herstellung von neuen chinazolinverbindungen und deren saeureadditionssalzen und optisch aktiven formen
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CA2489560A1 (en) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
WO2005037825A2 (en) * 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors

Also Published As

Publication number Publication date
CR9647A (es) 2008-09-09
PE20070113A1 (es) 2007-02-09
AU2006258059A1 (en) 2006-12-21
TW200716598A (en) 2007-05-01
AR057062A1 (es) 2007-11-14
JP2008543762A (ja) 2008-12-04
WO2006135649A2 (en) 2006-12-21
CA2611378A1 (en) 2006-12-21
WO2006135649A3 (en) 2007-02-15
US20070004763A1 (en) 2007-01-04
IL187685A0 (en) 2008-08-07
KR20080028913A (ko) 2008-04-02
EP1899319A2 (en) 2008-03-19
EA200800014A1 (ru) 2008-06-30
BRPI0611621A2 (pt) 2010-09-21
NO20080168L (no) 2008-03-07
GT200600254A (es) 2007-01-12

Similar Documents

Publication Publication Date Title
CR9647A (es) Moduladores de cinasa de aminoquinolina y amoniquinazolina
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
ECSP088573A (es) Triazolopiridazinas como moduladores de tirosina cinasa
CR9652A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
CR9650A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
ECSP109953A (es) Derivados de piridazinona
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
ECSP10010361A (es) Derivados de piridazinona
CL2012003637A1 (es) Compuestos derivados de quinazolina o triazolopiridina sustituidos, inhibidores selectivos de tirosina quinasa; medicamento; composicion farmaceutica; y su uso para tratar, prevenir o mejorar edema retiniano/macular, degeneración macular relacionada con la edad y derrame vascular retiniano relacionado con isquemia, entre otras.
EA200702136A1 (ru) Композиции станнсопорфина и их применение
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas
UA105483C2 (uk) Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k